Antisense Oligonucleotides for Targeted Apo(a) mRNA Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies are limited in effectively reducing apolipoprotein(a) levels to treat cardiovascular diseases, with existing compounds showing modest reductions and no direct clinical use targeting apo(a).
Innovation Solution
Development of apo(a) specific inhibitors, such as modified oligonucleotides, to target and reduce apo(a) mRNA and protein expression, including antisense oligonucleotides with specific nucleobase sequences and modifications, administered to modulate apo(a) levels in cells or tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing therapeutic compounds are used to reduce apolipoprotein(a) levels, then some reduction in apo(a) levels is achieved, but the reduction is only modest and insufficient for effective cardiovascular disease treatment
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to apo(a) mRNA to prevent protein translation. This intermediary approach allows specific targeting of apo(a) synthesis without affecting other lipoprotein pathways, achieving more effective and selective reduction compared to existing compounds
Solution Approach 2:
The invention modifies the chemical parameters of oligonucleotide molecules through various modifications (2'-O-methoxyethyl, phosphorothioate linkages, etc.) to optimize their binding affinity, stability, and biological activity, thereby achieving more effective apo(a) level reduction
2Adaptability or versatility
If no direct clinical use compounds targeting apo(a) are available, then current treatment options are limited, but developing new compounds requires extensive research and validation time
Solution Approach 1:
The patent performs preliminary actions by conducting extensive in vitro and in vivo studies, toxicity assessments, and mechanism of action investigations before clinical application. This preliminary validation framework accelerates future drug development by establishing a proven platform for apo(a) targeting
Solution Approach 2:
The antisense oligonucleotide mechanism provides self-service by specifically targeting and degrading apo(a) mRNA through endogenous cellular mechanisms (RNase H activation), reducing the need for complex external delivery systems and simplifying the development pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The apo(a) specific inhibitors effectively reduce both apo(a) mRNA and protein levels in a time- and dose-dependent manner, providing therapeutic benefits for cardiovascular and metabolic diseases by potentially lowering Lp(a) levels and reducing associated risks.
Implementation Method 1
The modified oligonucleotide has a nucleobase sequence that is complementary to a target segment of an apo(a) nucleic acid
Implementation Method 2
The internal region comprises a plurality of deoxynucleosides that support RNase H cleavage
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.